Lucid Diagnostics Inc., was incorporated in Delaware on May 8, 2018. The company is a commercial-stage medical diagnostic technology company focusing on millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simple reflux, which is at risk of developing esophageal precancerous lesions and cancers, especially highly lethal esophageal adenocarcinoma (EAC). The company believes that the lead product, the ESOGuard esophageal DNA test on samples collected using the ESOCheck esophageal cell collection device in a short, non-invasive office procedure, constitutes the first and only commercially available diagnostic test that can be used as a broad screening tool to prevent EAC death by early detection of esophageal precancerous lesions and cancer in at-risk GERD patients. The company believes that the impact of ESoGuard in preventing EAC deaths may be as great as the impact of extensive Pap test screening in preventing cervical cancer deaths.